Calidi Biotherapeutics Inc CLDI shares are trading lower by 59% to $0.25 during Tuesday’s session after the company announced the pricing of a $6.1 million public offering.
The offering includes various types of warrants with different exercise prices and expiration dates. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials.
The offering is expected to close around April 18, pending customary closing conditions, with Ladenburg Thalmann & Co. Inc. serving as the sole placement agent.
See Also: High-Interest Rates Could Cause ‘More Things To Break’ In US Economy By 2025, Warns Strategist
How To Buy CLDI Stock
By now you're likely curious about how to participate in the market for Calidi Biotherapeutics – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Calidi Biotherapeutics, which is trading at $0.28 as of publishing time, $100 would buy you 357.14 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
According to data from Benzinga Pro, CLDI has a 52-week high of $5.00 and a 52-week low of $0.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
